Glyset Vita100 IU/ml

Glyset Vita is a biphasic (premixed) insulin analog preparation indicated to improve glycemic control in adults and children with diabetes mellitus who require insulin therapy.

Established/FDA-approved uses

• Type 1 diabetes mellitus, as part of a regimen providing both rapid-onset and intermediate-duration insulin coverage (usually in patients who prefer fewer daily injections than a basal-bolus regimen).
• Type 2 diabetes mellitus, when oral antidiabetic agents alone no longer provide adequate glycemic control, either as monotherapy insulin or in combination with certain oral antidiabetic agents (e.g. metformin) under physician supervision.

Guideline-supported / practical use

Glyset Vita is commonly used twice daily (before breakfast and before the evening meal) to cover both mealtime glucose excursions and background insulin needs, particularly favored where a simplified regimen improves adherence.

It is not intended for use as the sole insulin regimen in situations requiring flexible, fully individualized basal-bolus dosing (such as tight control in pregnancy or very unpredictable meal schedules), where separate rapid- and long-acting insulins are generally preferred.

Insulin Aspart [Protamine Crystallised] is a biphasic suspension for injection containing two components of the rapid-acting insulin analog insulin aspart:

• Insulin aspart (soluble, rapid-acting fraction) - provides a fast onset of action to cover the glycemic rise after meals.
• Insulin aspart protamine (crystallised, intermediate-acting fraction) - insulin aspart complexed with protamine, which delays its absorption and prolongs its glucose-lowering action, functioning similarly to NPH-type intermediate insulin.

The two fractions are combined in a fixed premixed ratio (commonly 30% soluble insulin aspart / 70% protamine-crystallised insulin aspart) to provide combined rapid and intermediate coverage from a single injection.

Glyset Vita is a recombinant human insulin analog preparation used in the management of diabetes mellitus. It combines a fast-acting soluble insulin aspart fraction with a protamine-crystallised insulin aspart fraction that has been formulated to delay absorption, giving the product a biphasic (dual-peak) time-action profile.

It is supplied as a uniform white suspension for subcutaneous injection (via vial, prefilled pen, or cartridge, depending on local availability) and must be gently resuspended (rolled/tipped, not shaken vigorously) immediately before each dose until uniformly cloudy.

Glyset Vita belongs to the class of antidiabetic agents - insulins and analogs, specifically a premixed (biphasic) rapid- and intermediate-acting insulin analog.

Mechanism

Insulin Aspart [Protamine Crystallised] lowers blood glucose by binding to insulin receptors on target tissues (skeletal muscle, adipose tissue, liver), stimulating peripheral glucose uptake, promoting glycogen and lipid synthesis, and suppressing hepatic glucose production and lipolysis.

Pharmacokinetics

This combined profile gives Insulin Aspart [Protamine Crystallised] a rapid onset after injection with a more prolonged, intermediate tail of glucose-lowering activity, allowing it to cover both a meal and a portion of background insulin need from a single dose.

Glyset Vita is for subcutaneous injection only, given immediately before or shortly after a meal. Gently resuspend the suspension by rolling/tipping the pen or vial before every dose, inject into the abdomen, thigh, buttock, or upper arm, and rotate injection sites. Do not inject intravenously or intramuscularly, and do not share pens/needles between patients even after a needle change. See Dosage and Administration for full technique and precautions.

Several medicines can alter the glucose-lowering effect of Glyset Vita and increase the risk of hypoglycemia or hyperglycemia:

• Increased hypoglycemia risk: oral antidiabetic agents, other insulins, ACE inhibitors, monoamine oxidase inhibitors (MAOIs), non-selective beta-blockers, salicylates, and alcohol. Beta-blockers may also blunt or mask the warning symptoms of hypoglycemia (tremor, palpitations), delaying recognition.
• Reduced glucose-lowering effect (risk of hyperglycemia): corticosteroids, thiazide diuretics, thyroid hormones, oral contraceptives/estrogens, and sympathomimetics.
• Thiazolidinediones (e.g. pioglitazone): co-administration with insulin, including Glyset Vita, increases the risk of fluid retention and heart failure, particularly in patients with pre-existing cardiac disease; combined use requires cardiac monitoring.

Patients should inform their physician of all medicines, including over-the-counter drugs and herbal products, before starting Glyset Vita.

The most common and most serious adverse effect of Glyset Vita is hypoglycemia, which can range from mild (sweating, tremor, palpitations, hunger, confusion) to severe (seizure, loss of consciousness) and requires prompt treatment.

Other reported effects include:

• Injection-site reactions: redness, swelling, itching, or pain at the injection site.
• Lipodystrophy (thickening or pitting of fat tissue) with repeated injection at the same site.
• Weight gain and peripheral edema, particularly when glycemic control improves rapidly.
• Hypokalemia (low blood potassium), especially with concurrent illness, poor intake, or other potassium-lowering drugs.
• Rarely, generalized allergic reactions (rash, angioedema, bronchospasm, anaphylaxis).

Good glycemic control before and during pregnancy is important for both mother and fetus, and insulin therapy - including Glyset Vita - is a preferred option for controlling blood glucose in pregnant women with diabetes when insulin is needed, as insulin does not cross the placenta in clinically significant amounts. Nonetheless, Glyset Vita should be used in pregnancy only under close physician supervision, with dose requirements often changing across trimesters and around delivery; use only if clearly needed and as directed by the treating physician.

Insulin aspart passes into breast milk in only negligible amounts and is generally considered compatible with breastfeeding; however, breastfeeding mothers using Glyset Vita may need dose adjustment and should continue treatment only under medical supervision, monitoring the infant and maternal glucose control.

• Hypoglycemia: the most frequent risk with Glyset Vita; can occur from delayed/missed meals, unplanned exercise, alcohol intake, or dose errors. Patients and caregivers should be trained to recognize and treat early symptoms and to always carry a fast-acting source of glucose.
• Hypokalemia: monitor potassium in at-risk patients (e.g. concurrent illness, poor intake, potassium-lowering drugs).
• Injection site rotation: rotate sites within the same region to reduce lipodystrophy, which can affect insulin absorption.
• Illness, diet, and exercise changes: insulin requirements may rise (illness, stress, reduced activity) or fall (increased exercise, reduced food intake); dose must be reviewed with the physician during such changes.
• Renal or hepatic impairment: may reduce insulin clearance and increase hypoglycemia risk; monitor glucose more closely and adjust dose.
• Do not mix insulin types improperly or reuse needles/pens between patients.
• Never dilute or mix Glyset Vita with other insulins unless specifically instructed by a physician, as this can unpredictably alter its time-action profile.
• Use caution when driving or operating machinery if hypoglycemia risk is present.

Overdose of Glyset Vita causes hypoglycemia, which may present as sweating, tremor, palpitations, hunger, confusion, blurred vision, seizures, or loss of consciousness. Mild hypoglycemia can often be treated with oral fast-acting carbohydrate (e.g. glucose tablets, sugary drink) followed by a longer-acting carbohydrate snack. Severe hypoglycemia (confusion, seizure, unconsciousness) is a medical emergency - seek immediate medical attention or contact emergency services; a caregiver may administer glucagon if trained and available while awaiting help. Do not attempt to manage severe or persistent hypoglycemia at home without professional guidance.

Store unopened vials, cartridges, or pens in a refrigerator at 2-8°C; do not freeze, and discard if it has been frozen. Once in use, the pen/vial currently being used may be kept at room temperature (below 30°C), away from direct heat and light, for the period specified on the product label (typically up to about 4 weeks), after which any remaining medicine should be discarded. Keep out of reach of children, and always inspect for a uniform cloudy/white appearance after resuspension before injecting.

Pediatric use

Safety and efficacy of Glyset Vita in children have not been well established for this premixed formulation; use in pediatric patients should be individualized and supervised by a pediatric endocrinologist, with careful attention to hypoglycemia risk.

Elderly

Older patients may be more susceptible to hypoglycemia and its complications. Glyset Vita should be initiated conservatively with close glucose monitoring, particularly in those with renal or hepatic impairment or irregular meal patterns.

Renal/hepatic impairment

Reduced insulin clearance may increase hypoglycemia risk; monitor glucose closely and adjust dose as needed (see Precautions and Warnings).

Pregnancy and lactation

See Pregnancy and Lactation section above.

Glyset Vita is generally used long-term/chronically for ongoing glycemic control in diabetes mellitus, as diabetes is a chronic condition; there is no fixed treatment duration. Dose and regimen are periodically reviewed and adjusted by the treating physician based on blood glucose monitoring, HbA1c, and clinical status.

Insulin Aspart [Protamine Crystallised] belongs to the insulin and insulin analog drug class, specifically a premixed biphasic insulin analog combining rapid-acting and intermediate-acting (protamine-complexed) components, used as an antidiabetic/antihyperglycemic agent.

Insulin Aspart [Protamine Crystallised] works by supplying exogenous insulin activity in two phases. The soluble insulin aspart fraction binds rapidly to insulin receptors, promoting quick glucose uptake by muscle and fat cells and suppressing hepatic glucose output, closely mimicking the mealtime insulin surge. The protamine-crystallised insulin aspart fraction dissolves and is absorbed more slowly from the injection site as the protamine-insulin complex gradually dissociates, providing a prolonged intermediate-acting supply of insulin that supports background glycemic control between meals.

B

Glyset Vita has not been well established as safe and effective for use in pediatric patients in this specific premixed formulation. When insulin therapy is required in children, treatment is generally individualized by a pediatric endocrinologist, and premixed regimens like Glyset Vita are used cautiously only when appropriate for the child's meal pattern and self-management ability, with close monitoring for hypoglycemia given children's variable food intake and activity levels.